Introduction: The role of intracoronary (IC) eptifibatide in primary percutaneous coronary
INTRODUCTION
Despite the established role of primary percutaneous coronary intervention (PCI) in improving the outcomes in patients presenting with ST segment elevation myocardial infarction (STEMI), a significant portion of patients do not achieve optimal angiographic or clinical reperfusion outcomes [1] . This is in part related to what is known as the ''no-reflow'' phenomenon, which was described as microvascular obstruction (MVO) despite angiographic vessel patency. The incidence of no-reflow varied from 12% to 29% in prior studies [2, 3] and is associated with increased infarct size, reduced left ventricular (LV) function, and increased mortality in STEMI patients [1] .
Glycoprotein (GP) IIb/IIIa inhibitors have been a field of interest for many studies as an intervention to reduce MVO and no-reflow during primary PCI. Results regarding its efficacy as well as the preferred route of administration, intracoronary (IC) versus intravenous (IV), have been controversial [4, 5] . Overall, the existing body of evidence is in favor of using GP IIb/IIIa inhibitors as a bailout therapy in selective conditions with heavy thrombus burden or procedural-related thrombotic complications, rather than using them routinely in all patients [6, 7] .
The duration of ischemia defined as the time elapsed from symptom onset until therapy was proven to correlate inversely with myocardial salvage as well as survival rates in patients with STEMI [8] [9] [10] . Late presenters are associated with higher magnitude of infarct size and microvascular obstruction compared to STEMI patients who undergo early recanalization of occluded arteries [11] . Moreover, thrombus composition tends to differ according to the time of presentation. Fresh occlusive thrombi are rich in platelets and loose fibrin strands, whereas older thrombi tend to be rich in red blood cells and fibrin [12] . The efficacy of fibrinolytic therapy has been shown to be strongly impacted by presentation time, with best outcomes in patients receiving the drug within 2 h from symptom onset [13] .
In this hypothesis-generating study, we sought to evaluate the benefit of routine IC eptifibatide use during primary PCI in early STEMI presenters compared to late STEMI presenters. [14] . Patients were included in the study if the onset of symptoms was within no more than 12 h and they were eligible for primary PCI. Patients were excluded if they (1) had history of ischemic stroke within the previous 30 days or intracranial hemorrhage at any time;
METHODS
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(2) presented with cardiogenic shock (i.e., Killip class IV); (3) had platelet count less than 100,000 cells/lL; (4) initially received fibrinolytic therapy; or (5) had history of PCI or coronary artery bypass grafting (CABG).
Generation of Treatment Assignment
After confirming the eligibility to be included in our study, patients were classified on the basis Clopidogrel (75 mg) was continued daily for at least 12 months after PCI.
All patients had laboratory investigations done including daily complete blood count (CBC), serum creatinine level, serum troponin on admission and after 4-6 h, and creatine kinase myocardial band (CKMB) levels every 6 h till normalization. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.
As this study was intended as a pilot study to test this hypothesis, the study was not registered. The authors intend to register the larger study once it is pursued.
Outcomes and Definitions
The main outcome of this study included post-primary PCI myocardial blush grading (MBG). MBG was evaluated in left lateral view after the PCI; and outcome measure of achievement of MBG C2 was defined as moderate opacification or more of the myocardium, and cleared normally at the end of the washout phase [15] . An independent cardiologist, expert in cardiac catheterization, who was unaware of the randomization reviewed the coronary angiography to assess the MBG and the corrected thrombolysis in myocardial infarction frame count (cTFC). (b) Achievement of full ST segment resolution (STR) after primary PCI was defined as C70% resolution of the ST segment elevation [17] . ST segment elevation was evaluated in 12-lead EKG done within 10 min of the first medical contact and at 60 min after reperfusion in the lead of maximum ST segment elevation. PR segment was the reference baseline.
Other Outcomes of Interest Included
Evaluation was conducted by a single investigator blinded to randomization. (c) Infarct size after primary PCI was assessed by the peak levels of CKMB enzymes.
Statistical analysis
Statistical analyses were performed using SPSS were quoted as two-tailed probabilities, and judged at the 5% level.
RESULTS
Of 78 patients screened for enrollment, 70 patients were eligible for inclusion in the study (one patient had a prior PCI, three patients had prior CABG, two patients had a platelet count \100,000 cells/lL, while two patients had inadequate angiographic images to assess MBG). The patients were classified according to their symptom-to-door time into early presenters (\3 h, n = 34) versus late presenters (C3 h, n = 36). Patients in each arm were further randomized into intervention (receiving IC eptifibatide during the primary PCI) and control groups. The distribution of all baseline characteristics, except that of the gender, was similar between the IC eptifibatide and control groups (Table 1) . Among early presenters, there were significantly more female patients in the IC eptifibatide group compared to the control group (p = 0.018).
In the early presenters group, no difference was observed in the main outcome of MBG C2 in the intervention group compared with control group (100% vs 82%; RR = 1.2; 95% CI 0.97-1.51; p = 0.23) (Fig. 1) . The eptifibatide subgroup, however, was associated with improved median cTFC (19 vs 25; r = 0.6; p\0.001) (Fig. 2) and lower peak CKMB values (210 vs 260 IU/L; r = 0.5; p = 0.006) (Fig. 3) , compared with the control subgroup. STR C70% was not significantly different between both subgroups (65% vs 35%; RR = 1.8; 95% CI 0.9-3.8; p = 0.09). No difference in these results was observed after adjustment for female gender, which was over-represented in the IC eptifibatide subgroup.
In the late presenters arm, the eptifibatide subgroup was associated with improved main outcome of MBG C2 (100 vs 50%; RR = 2; 95% CI 1.3-3.2; p = 0.001) compared with the control subgroup (Fig. 1) . Similar to early presenters, the eptifibatide subgroup was showed improvement in cTFC and infarct size determined by peak CKMB levels but without significant difference in STR C70%.
The role of routine use of GP IIb/IIIa inhibitors to improve myocardial reperfusion and prevent the no-reflow phenomenon during primary PCI is unclear [19] [20] [21] , and the bailout use of these agents during circumstances at high risk of thrombus-related complications remains the standard protocol [14] . Furthermore, the appropriate route of administration of GP IIb/ IIIa (intracoronary versus intravenous) is still debatable [5, [22] [23] [24] . IC eptifibatide was found to achieve better outcomes compared to conventional PCI and aspiration thrombectomy devices during primary PCI in STEMI patients [4] . Fig. 2 Box plot indicating the distribution of cTFC between control and IC eptifibatide groups and between early and late presenters. cTFC corrected TIMI frame count, IC intracoronary Fig. 3 Box plot indicating the distribution of peak CKMB between control and IC eptifibatide groups and between early and late presenters. CKMB creatine kinase myocardial band, IC intracoronary Table 2 Comparison of the outcome variables between IC eptifibatide and control groups The objective of our study was driven by the fact that the presentation time for STEMI patients significantly impacts the outcomes of primary PCI. Studies have shown an increase in short-and long-term mortality with progressive delays between symptom onset and PCI [25] , where each 30-min delay from symptom onset was associated with around 8% increase in the relative risk of mortality at 1 year [26] .
To our knowledge, this is the first study to evaluate whether IC eptifibatide in addition to primary PCI would reduce the risk of no-reflow compared with conventional care based on pain-to-door time of STEMI patients. Hence, a 2 9 2 study protocol was performed, where we divided the included patients into early and late STEMI presenters, and then randomized each arm to receive either primary PCI with IC eptifibatide versus conventional primary PCI.
We chose to provide eptifibatide through IC perfusion catheter, rather than IV route, to achieve higher concentration of the drug at the site of the thrombus, aiming for superior dissociation of the bound fibrinogen and improvement of microvascular perfusion [27, 28] .
The superior achievement of the main outcome of MBG C2 seen with eptifibatide in late STEMI presenters compared to the control group, and the failure to observe such benefit in the early presenters arm, could be explained by the propensity of the former arm towards higher microvascular obstruction [11] . It might also be attributed to the difference in thrombus composition in late versus early presenters [12] . Ischemic time was proven to highly impact thrombi composition, through a positive correlation with fibrin content and negative correlation with platelet content and soluble CD40 ligand [29] . Furthermore, recent studies have demonstrated that higher concentrations of GP IIb/IIIa receptor antagonists are necessary to effectively disaggregate stable and aged aggregates compared with newly formed thrombi [30] . The absence of an observed clinical benefit through lack of improvement in STR C70% is likely related to the small sample size of our study.
The use of IC eptifibatide was associated with improvement in cTFC as well as reduction in peak CKMB values compared with conventional care in both early and late presenters. However, the discrepancy between such benefit and lack of improvement of MBG in the early presenters could be explained by the fact that MBG is a more sensitive indicator of microvascular perfusion compared with TIMI flow which mainly represents macrovascular patency [15, 16, 31, 32] .
Limitations
We acknowledge the following as limitations for our study. This study was conducted in a single center with a small sample size, which could have precluded a more robust analysis. Also, the study was not double-blinded.
However, seeking to eliminate potential source of bias, investigators evaluating end points were blinded to the treatment groups. In addition, the use of more advanced modalities such as cardiac magnetic resonance would have provided superior assessment of outcomes (e.g., infarct size). 
CONCLUSION
